ArticleMolecular neurobiology2025
Chrysin Improves Cognitive Dysfunction in Rats with Intracerebral Hemorrhage by Regulating the Nrf2/GPX4 Pathway to Inhibit Ferroptosis.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chrysin Attenuates Dry Eye Progression by Suppressing NOX2-Dependent Ferroptosis and STING/NLRP3-Mediated Inflammatory Responses.Investigative ophthalmology & visual science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intracerebral hemorrhage (ICH) is a serious hemorrhagic stroke. Secondary nerve injury can cause nerve cell ferroptosis (FER), which promotes oxidative stress and inflammatory response and has been associated with poor prognosis in patients. Chrysin (CHR) has various bioactivities, such as antioxidative stress, anti-inflammatory, anti-FER, and neuroprotective effects. However, the role and mechanism of CHR in ICH remain undetermined. Therefore, this study established the rat ICH model using an autologous blood injection to investigate the brain tissue and hippocampal neuron morphological changes via hematoxylin-eosin staining, Nissl staining, and transmission electron microscopy. Furthermore, FER-related indicators were detected using a reagent kit and western blotting. Moreover, the Morris water maze test was carried out to assess the cognitive function of rats. The results indicated that CHR treatment significantly reduced FER, oxidative stress, inflammation, and nerve injury in the hippocampus of ICH rats and improved their cognitive function. In addition, ML385, the Nrf2 inhibitor, reversed the CHR-induced upregulation of the Nrf2/GPX4 signaling pathway and aggravated cognitive dysfunction in ICH rats. In conclusion, this study indicated that CHR inhibits FER by regulating the Nrf2/GPX4 signaling pathway to alleviate nerve injury and improve cognitive dysfunction in ICH rats. Therefore, CHR can be employed as a new strategy for treating ICH.
Indexed as
Identifiers
41231360What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.